X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5062) 5062
Publication (273) 273
Book Review (66) 66
Book Chapter (30) 30
Magazine Article (16) 16
Dissertation (7) 7
Conference Proceeding (3) 3
Data Set (2) 2
Newspaper Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3198) 3198
male (2414) 2414
levodopa (2023) 2023
parkinson disease - drug therapy (2002) 2002
female (1959) 1959
parkinson's disease (1858) 1858
levodopa - therapeutic use (1752) 1752
clinical neurology (1704) 1704
middle aged (1567) 1567
aged (1431) 1431
index medicus (1384) 1384
neurosciences (1084) 1084
animals (1054) 1054
antiparkinson agents - therapeutic use (980) 980
levodopa - administration & dosage (962) 962
carbidopa - therapeutic use (954) 954
levodopa - adverse effects (861) 861
adult (821) 821
l-dopa (800) 800
levodopa - pharmacology (733) 733
pharmacology & pharmacy (714) 714
dopamine (673) 673
drug combinations (671) 671
dopa (659) 659
carbidopa - administration & dosage (603) 603
antiparkinson agents - adverse effects (578) 578
parkinson disease - physiopathology (568) 568
carbidopa (566) 566
drug therapy, combination (562) 562
parkinsons-disease (555) 555
antiparkinson agents - administration & dosage (548) 548
rats (539) 539
neurology (507) 507
motor fluctuations (504) 504
double-blind (453) 453
treatment outcome (422) 422
dose-response relationship, drug (412) 412
parkinsons disease (404) 404
carbidopa - pharmacology (392) 392
levodopa - pharmacokinetics (382) 382
time factors (369) 369
carbidopa - adverse effects (360) 360
pharmacokinetics (354) 354
movement disorders (347) 347
dopamine - metabolism (333) 333
dyskinesia (325) 325
double-blind method (318) 318
psychiatry (313) 313
parkinson disease - complications (310) 310
therapy (303) 303
parkinson’s disease (287) 287
aged, 80 and over (257) 257
basal ganglia (245) 245
analysis (243) 243
brain (238) 238
levodopa - blood (238) 238
neurodegenerative diseases (236) 236
antiparkinson agents - pharmacology (234) 234
entacapone (230) 230
disease (223) 223
antiparkinson agents - pharmacokinetics (219) 219
drug therapy (217) 217
parkinson disease (208) 208
care and treatment (202) 202
dopamine agents - therapeutic use (202) 202
parkinson disease - metabolism (202) 202
dopamine agonists - therapeutic use (201) 201
severity of illness index (201) 201
drug administration schedule (200) 200
quality of life (194) 194
parkinson disease - diagnosis (191) 191
motor activity - drug effects (187) 187
parkinson disease - therapy (187) 187
follow-up studies (183) 183
levodopa - metabolism (176) 176
medicine & public health (174) 174
disease models, animal (172) 172
fluctuations (169) 169
catechol o-methyltransferase inhibitors (167) 167
drug interactions (167) 167
corpus striatum - drug effects (163) 163
corpus striatum - metabolism (161) 161
parkinsonism (161) 161
research (161) 161
delayed-action preparations (158) 158
clinical trials as topic (157) 157
phenols (157) 157
administration, oral (156) 156
diagnosis (155) 155
deep brain stimulation (153) 153
medicine, general & internal (153) 153
patients (153) 153
parkinson disease - blood (152) 152
rats, sprague-dawley (152) 152
catechol-o-methyltransferase (150) 150
dyskinesias (150) 150
nervous system diseases (149) 149
metabolism (148) 148
dopamine agents - pharmacology (146) 146
quality-of-life (146) 146
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4819) 4819
Russian (60) 60
German (58) 58
Spanish (58) 58
Japanese (24) 24
French (19) 19
Hungarian (16) 16
Italian (15) 15
Polish (14) 14
Chinese (6) 6
Dutch (6) 6
Slovak (3) 3
Czech (2) 2
Romanian (2) 2
Ukrainian (2) 2
Bulgarian (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 995 - 1003
IPX066 (extended‐release carbidopa‐levodopa [ER CD‐LD]) is an oral extended‐release capsule formulation of carbidopa and levodopa. The single‐dose... 
pharmacokinetics | Parkinson's disease | levodopa | extended release | IPX066 | Carbidopa | Analysis | Entacapone | Dosage and administration | Pharmacokinetics | Comparative analysis | Dopa
Journal Article
Journal Article
Annals of Neurology, ISSN 0364-5134, 07/2010, Volume 68, Issue 1, pp. 18 - 27
Journal Article
Movement Disorders, ISSN 0885-3185, 04/2015, Volume 30, Issue 4, pp. 500 - 509
Journal Article
AAPS Journal, ISSN 1550-7416, 04/2013, Volume 15, Issue 2, pp. 316 - 323
Motor complications of Parkinson's disease (PD) are a consequence of pulsatile dopaminergic stimulation from standard oral levodopa therapy. Levodopa-carbidopa... 
Duodopa | Levodopa-carbidopa intestinal gel | Parkinson's disease | Pharmacokinetics | LCIG | ENTACAPONE | CONTINUOUS DOPAMINERGIC STIMULATION | ORAL LEVODOPA | LEVODOPA/CARBIDOPA | RELEASE | TRANSPORT | THERAPY | FLUCTUATIONS | L-DOPA | PHARMACOLOGY & PHARMACY | ABSORPTION | Humans | Middle Aged | Intubation, Gastrointestinal - instrumentation | Levodopa - pharmacokinetics | Male | Tyrosine - blood | Parkinson Disease - drug therapy | Tyrosine - analogs & derivatives | Intestinal Absorption | Jejunum - metabolism | Levodopa - chemistry | Sweden | Levodopa - administration & dosage | Biotransformation | Carbidopa - adverse effects | Antiparkinson Agents - chemistry | Female | Tyrosine - pharmacokinetics | Carbidopa - blood | Carbidopa - administration & dosage | Gels | Infusion Pumps | Carbidopa - pharmacokinetics | Carbidopa - chemistry | Antiparkinson Agents - adverse effects | Levodopa - blood | Chemistry, Pharmaceutical | Antiparkinson Agents - pharmacokinetics | Antiparkinson Agents - blood | Levodopa - adverse effects | Parkinson Disease - diagnosis | Aged | Antiparkinson Agents - administration & dosage | Parkinson Disease - blood | Drug Combinations | Germany | Complications and side effects | Neurosciences | Carbidopa | Metabolites | Universities and colleges | Dopa | Oral medication | Clinical Medicine | Neurology | Neurologi | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Parkinsonism and Related Disorders, ISSN 1353-8020, 08/2019, Volume 65, pp. 131 - 138
Dopamine replacement via levodopa (LD) remains the most effective treatment for Parkinson's disease (PD), yet its use is often associated with motor... 
Parkinson's disease | Levodopa treatment | Motor fluctuation | Continuous dopaminergic stimulation | LEVODOPA/CARBIDOPA | MOTOR | ABSORPTION | CLINICAL NEUROLOGY | DELIVERY | Drugs | Medical research | Drug delivery systems | Carbidopa | Medicine, Experimental | Dopa | Vehicles
Journal Article
Journal Article